IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

Revolutionizing Alzheimer's Care: Emerging Therapeutic Approaches

Ms. Aakanksha R. Patil[1], Mr. Gayatri L. Munde[1],
Prof. Mr. Devanand H. Dongre[2], Prof. Dr. Prafulla R Tathe[3].
Students, Bachelor of Pharmacy Final Year, Samarth College of Pharmacy, Deulgaon Raja[1].
Associate Professor, Department of Chemistry, Samarth College of Pharmacy, Deulgaon Raja[2]
Professor cum Principal, Department of Pharmacology, Samarth College of Pharmacy, Deulgaon Raja[3]

Abstract: *This review explores the recent breakthroughs in Alzheimer's disease (AD) research and emerging therapeutic approaches aimed at transforming the management of this debilitating neurodegenerative disorder. As Alzheimer's continues to represent a significant global health challenge, novel therapies targeting the underlying biological mechanisms, such as amyloid plaques, tau tangles, neuroinflammation, and neurodegeneration, are being investigated. Additionally, non-pharmacological interventions and advancements in diagnostic technologies are discussed as complementary strategies in the fight against Alzheimer's disease. This paper provides an overview of the most recent developments in Alzheimer's therapeutics and their potential to revolutionize patient care.Alzheimer's disease (AD) is an aging-related Irreversible neurodegenerative disease affecting mostly the elderly population. The main pathological features of AD are the extracellular Aβ plaques generated by APP cleavage through the amyloidogenic pathway, the intracellular neurofibrillary tangles (NFT) resulting from the hyperphosphorylated tau proteins, and cholinergic neurodegeneration. However, the actual causes of AD are unknown, but several studies suggest hereditary mutations in PSEN1 and -2, APOE4, APP, and the TAU genes are the major perpetrators..*

Keywords: Alzheimer's disease (AD), Neurodegenerative disorder, Amyloid plaques, Tau tangles, Neuroinflammation, Neurodegeneration

I. INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia, characterized by progressive memory loss, cognitive decline, and functional impairments.Alzheimer's disease (AD) ranks as the top disease with the most prevalent irreversible neurodegenerative conditions worldwide, primarily impacting individuals aged 65 and older, with its prevalence increasing exponentially over time, doubling approximately every 5 years.[16,17]Despite decades of research, no cure exists, and current treatments provide only symptomatic relief. However, recent advancements in neuroscience, pharmacology, and biotechnology have led to the development of novel approaches aimed at modifying the course of the disease rather than simply alleviating symptoms. This review summarizes the most promising emerging therapies in Alzheimer's disease care.Currently, it is negatively impacting nearly 50 million individuals, with the number of cases being projected to reach around 150 million by the year 2050.[17]

In 1906, Alois Alzheimer introduced his initial hallmark case and outlined the disease's pathological characteristics during the 37th meeting of the Southwestern German Psychiatrists gathering. AD was named after him by his co-worker Emil Kraepelin in 1910. Electron microscopy analysis was then performed by Robert Terry and Michael Kidd, who showed the presence of neurofibrillary tangles (NFTs) in brain biopsies of two advanced AD patients. This discovery further led to subsequent research on the pathological features and mechanism of AD.[18-20] AD is rapidly evolving into one of the most economically burdensome and life-threatening conditions in the 21st century since AD affects not only the daily activities of individual patients but also their family members and caretakers.[21]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025



Figure 01: Pathophysiology of Alzheimer's disease

II. PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE:

Alzheimer's disease is characterized by two major pathological features: amyloid-beta plaques and tau tangles[4]. Amyloid plaques form when amyloid-beta peptides aggregate into extracellular deposits, while tau tangles result from the abnormal phosphorylation of tau proteins, leading to intracellular neuronal damage[8]. Chronic neuroinflammation and oxidative stress are other critical contributors to disease progression [5].The primary pathological features of Alzheimer's disease include the accumulation of amyloid-beta plaques, tau tangles, neuroinflammation, and neurodegeneration



Figure 02:Aβ Aggregation: The amyloid-beta peptide

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

1. Amyloid-beta Plaques

The accumulation of amyloid-beta (Aβ) plaques is one of the hallmark features of Alzheimer's disease. Amyloid-beta is derived from the amyloid precursor protein (APP), a transmembrane protein that undergoes enzymatic cleavage by β-secretase and γ-secretase enzymes. The resulting amyloid-beta peptides (Aβ40 and Aβ42) aggregate and form extracellular plaques in the brain, particularly in areas critical for memory, such as the hippocampus and cerebral cortex.[4]

Mechanism:

Aβ Aggregation: The amyloid-beta peptide undergoes aggregation into fibrils, which then form extracellular amyloid plaques. This accumulation of plaques disrupts cell-to-cell communication and leads to synaptic dysfunction.[26]

2. Tau Tangles

Another key feature of Alzheimer's disease is the formation of tau tangles inside neurons. Tau is a microtubule-associated protein that stabilizes microtubules, which are essential for intracellular transport. In AD, tau undergoes hyperphosphorylation, a process that causes it to detach from microtubules and form neurofibrillary tangles within neurons.[22]

Mechanism:

Hyperphosphorylation of Tau: Tau's hyperphosphorylation leads to its destabilization and aggregation into paired helical filaments that form neurofibrillary tangles. These tangles disrupt neuronal transport, impairing synaptic function and contributing to neuronal death.[27]

3. Neuroinflammation

Neuroinflammation plays a significant role in Alzheimer's disease progression. Activated microglia, the resident immune cells in the brain, become overactive in response to amyloid plaques and other neuronal damage. While microglia are involved in normal maintenance and defense mechanisms, their chronic activation leads to the release of pro-inflammatory cytokines, free radicals, and other neurotoxic substances that exacerbate neuronal damage.[5]

Mechanism:

Microglial Activation: Microglia, the resident immune cells of the brain, become activated in Alzheimer's disease in response to amyloid-beta plaques. Activated microglia release pro-inflammatory cytokines, which can exacerbate neuronal damage.[5]

Astrocytes: Astrocytes also play a role in neuroinflammation by releasing inflammatory mediators that can contribute to neuronal toxicity.[28]

4. Oxidative Stress

Oxidative stress refers to an imbalance between the production of reactive oxygen species (ROS) and the brain's ability to detoxify them. This leads to neuronal damage, which is particularly evident in Alzheimer's disease.

Mechanism:

Free Radicals: The accumulation of amyloid-beta plaques and tau tangles leads to the production of free radicals and ROS, which damage cellular components such as lipids, proteins, and DNA[23].

5. Neurodegeneration and Synaptic Loss:

Neurodegeneration in Alzheimer's disease is characterized by the progressive loss of neurons, particularly in regions critical for memory, such as the hippocampus and cortex. This leads to atrophy of the brain and loss of cognitive function.

Mechanism:

Neuronal Death: The toxic effects of amyloid-beta, tau tangles, oxidative stress, and neuroinflammation contribute to neuronal death. This degeneration leads to synaptic loss, which is closely associated with cognitive decline in Alzheimer's[24].

Brain Atrophy: As neurons die, the brain undergoes atrophy, which is often observed on imaging as shrinking of the hippocampus and cortex.[25]

III. CURRENT THERAPEUTIC APPROACHES IN ALZHEIMER'S DISEASE

Existing treatments, such as acetylcholinesterase inhibitors (donepezil, rivastigmine) and NMDA antagonists (memantine), temporarily alleviate symptoms but do not modify the disease course [1]. In recent years, amyloid-targeting

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

drugs such as Aducanumab and Lecanemab have gained attention for their potential to reduce amyloid plaques and slow disease progression [13].Cholinesterase inhibitors (ChEIs)-donepezil (Aricept), rivastigmine (Razadyne), and galantamine (Exelon),[2] N-methyl-D-aspartate (NMDA) antagonis-;memantine(Namenda), monoclonal antibodies-aducanumab and lecanemab.

Pharmacological Approaches

The pharmacological basis for AD treatments, whether using cholinesterase inhibitors or memantine alone or ultimately combining them as an add-on dual-combination therapy, has consistently shown advantages in both the short and long terms. These treatments have been proven to slow down cognitive and functional decline, mitigate the disease onset and impact neuropsychiatric symptoms, and postpone the need for nursing home care, but all were ineffective in extending the time of life until death.[30]

Memantine was the most recent FDA-approved therapy for moderate to severe AD, where approval was granted in 2003, and it continues to be the only medication in its category. It impacts glutamatergic transmission and operates as a blocker with low to moderate affinity to NMDA receptors, accordingly inhibiting the increased calcium influx and oxidative stress.[31]It is given as a stand-alone treatment or in conjunction with a ChEI, often as an addition to the existing ChEI therapy.[30]

Non-Pharmacological Approaches:

Research on non-pharmacological interventions suggests that physical activity, cognitive training, and dietary modifications can improve brain health. The MIND diet (a hybrid of the Mediterranean and DASH diets) has been linked to a slower cognitive decline.[10]

IV. EMERGING THERAPEUTIC STRATEGIES

4.1 Amyloid and Tau Targeting Therapies:

Anti-Amyloid Agents: The development of monoclonal antibodies targeting amyloid plaques has shown promise. Aducanumab, the first FDA-approved amyloid-targeting drug, has demonstrated the ability to reduce amyloid deposits in the brain, although its clinical efficacy remains debated [12].

Tau-based Therapies: Tau-targeting therapies aim to prevent the aggregation of tau protein. Inhibition of tau phosphorylation or the use of anti-tau antibodies is an area of intense investigation [2].

4.2 Gene Therapy and Genetic Modifications:

Gene therapy strategies focus on altering the expression of genes associated with Alzheimer's risk, such as the APOE4 allele[6]. CRISPR-Cas9 gene-editing technology is being investigated for its potential to target genetic mutations directly involved in the pathogenesis of Alzheimer's[11].

4.3 Immunotherapies:

Vaccines: Active immunization strategies aim to stimulate the immune system to clear amyloid plaques and tau tangles. Vaccines targeting amyloid-beta are currently in clinical trials, with ACC-001 and AADvac1 showing early promise [12].

Immunomodulation: Modulating the immune system to reduce neuroinflammation could play a significant role in Alzheimer's therapy. Drugs such as XPro1595 are being tested for their ability to reduce harmful microglial activation [14].

4.4 Anti-Inflammatory and Neuroprotective Strategies:

Neuroinflammation is a central feature of Alzheimer's, and anti-inflammatory agents are being developed to mitigate neuronal damage. The anti-inflammatory drug, lenalidomide, has demonstrated neuroprotective effects in early trials[3]. Other drugs aim to reduce oxidative stress or promote synaptic plasticity [9].

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

4.5 Stem Cell Therapy and Regenerative Medicine:

Stem cell therapy aims to regenerate damaged brain tissue by replacing lost neurons or promoting neurogenesis. While still in early stages, induced pluripotent stem cells (iPSCs) have shown potential in restoring cognitive function in animal models of Alzheimer's [15].

V. ADVANCES IN DIAGNOSTICS

Imaging Techniques: PET scans and MRI allow for the in vivo visualization of amyloid plaques, tau tangles, and brain atrophy, enabling early detection [7].

Blood-Based Biomarkers: Advances in blood biomarkers, such as phosphorylated tau and amyloid-beta levels, have made early diagnosis more feasible [11].

VI. CHALLENGES IN ALZHEIMER'S THERAPY

While promising, many Alzheimer's clinical trials have faced setbacks. The failure of anti-amyloid therapies to produce consistent clinical benefits highlights the complexity of the disease[3]. Moreover, ethical concerns surrounding genetic modifications, patient consent, and the accessibility of new treatments need to be addressed.

Complex Pathophysiology: Alzheimer's disease is characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain. However, the exact mechanisms leading to these pathological changes are not fully understood.[3233]

Diagnosis: Early and accurate diagnosis of Alzheimer's disease remains a significant challenge. Current diagnostic methods rely heavily on clinical symptoms and imaging techniques, which may not detect the disease in its early stages.[32]

Therapeutic Development: Despite extensive research, there are no treatments that can halt or reverse the progression of Alzheimer's disease. Most current therapies only provide symptomatic relief2.[32,33]

Biomarker Identification: Identifying reliable biomarkers for early diagnosis and monitoring disease progression is crucial. However, the multifactorial nature of Alzheimer's disease complicates this process.[33]

Societal and Economic Impact: Alzheimer's disease imposes a significant burden on patients, caregivers, and healthcare systems. The cost of care and the emotional toll on families are substantial.[32]

Research and Funding: There is a need for increased funding and research efforts to better understand the disease and develop effective treatments.[32]

VII. FUTURE DIRECTIONS

1. Early Detection and Diagnosis

Biomarkers: Advances in the identification of biomarkers, such as beta-amyloid and tau proteins, as well as other molecular markers, are essential for early detection.

Blood tests and imaging techniques (e.g., PET scans) are becoming more refined to detect Alzheimer's in its early stages, even before symptoms appear.[34]

Genetic Testing: Research into genetic markers, such as the APOE gene, may help predict susceptibility to Alzheimer's, allowing for earlier interventions.[35]

2. Combination Therapy:

Researchers are investigating the use of combination therapies that target multiple pathological mechanisms simultaneously. This approach aims to maximize therapeutic effects by addressing various aspects of the disease.[36]

3. Lifestyle Interventions

Research into the role of lifestyle factors (e.g., diet, exercise, sleep, cognitive training, and social engagement) in Alzheimer's prevention and progression is gaining momentum. Evidence suggests that maintaining a healthy brain through lifestyle modifications could help delay the onset or slow the progression of Alzheimer's.[37]

4. Oral Medications:

The development of oral medications, such as ALZ-801, offers a more convenient and accessible treatment option compared to traditional intravenous infusions[38]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

5. Cognitive Enhancers

While current medications mainly alleviate symptoms, new cognitive enhancers are under investigation to improve memory, attention, and other cognitive functions in Alzheimer's patients. These therapies aim to treat the symptoms more effectively and improve the quality of life.[39]

VIII. CONCLUSION

Emerging therapeutic approaches, such as amyloid and tau targeting, gene therapy, stem cell research, and personalized treatment plans, hold the potential to significantly alter the course of Alzheimer's disease. While challenges remain, recent advancements provide hope for improving the lives of patients and caregivers in the near future.the future of Alzheimer's disease research and treatment is promising, with significant advances being made in early diagnosis, disease-modifying therapies, and understanding the disease's complex pathophysiology.

Furthermore, precision medicine, which tailors treatments based on genetic, environmental, and lifestyle factors, holds the potential to provide more personalized and effective interventions for patients.

In addition to pharmacological treatments, lifestyle interventions are emerging as vital components of a comprehensive care strategy. Regular exercise, cognitive training, and a balanced diet not only promote brain health but also offer a means of delaying the onset and progression of the disease.Additionally, lifestyle changes like staying active, eating a healthy diet, and keeping the mind engaged are becoming important in both preventing and managing Alzheimer's. These strategies, combined with new medical treatments, offer a more comprehensive approach to care.

While there are still challenges to overcome, such as getting treatments past the blood-brain barrier and fully understanding how Alzheimer's works, the future is promising. With continued research and innovation, we're getting closer to finding treatments that can slow, stop, or even cure Alzheimer's, ultimately improving the lives of those affected.

REFERENCES

[1]. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, (1).

[2]. Congdon, E. E., & Sigurdsson, E. M. (2018). Tau-targeting therapies for Alzheimer's disease: challenges and progress. Trends in Molecular Medicine, 24(4), 304-320.

[3]. Cummings, J., Lee, G., Ritter, A., &Zhong, K. (2020). Alzheimer's disease drug development pipeline: 2020. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1), e12050.

[4]. Hardy, J., &Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353-356.

[5]. Heneka, M. T., Carson, M. J., El Khoury, J., et al. (2015). Neuroinflammation in Alzheimer's disease. The Lancet Neurology, 14(4), 388-405.

[6]. Holtzman, D. M., et al. (2012). APOE and Alzheimer's disease: Risk, mechanisms, and therapy. Nature Reviews Neurology, 8(11), 685-695.

[7]. Jagust, W. J. (2018). Imaging the evolution of Alzheimer's disease: The role of positron emission tomography and magnetic resonance imaging. Molecular Psychiatry, 23(10), 1773-1785.

[8]. Karch, C. M., &Goate, A. M. (2015). Alzheimer's disease genetics and mechanisms. Current Neurology and Neuroscience Reports, 15(6), 59.

[9]. Khurana, V., et al. (2012). Neuroprotective mechanisms of some novel agents in Alzheimer's disease. Pharmacology & Therapeutics, 134(2), 206-220.

[10]. Morris, M. C., et al. (2015). MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's & Dementia, 11(9), 1007-1014.

[11]. Palmqvist, S., et al. (2020). Performance of new Alzheimer's disease blood biomarkers: the ABtest study. The Lancet Neurology, 19(3), 220-229.

[12]. Sevigny, J., et al. (2016). The antibody aducanumab reduces amyloid-β plaques in Alzheimer's disease. Nature, 537(7618), 50-56.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

[13]. Salloway, S., et al. (2022). Lecanemab in early Alzheimer's disease. New England Journal of Medicine, 388(7), 549-559.

[14]. Tchekmedyian, N. S., et al. (2022). Microglial modulation in Alzheimer's disease. The Journal of Neuroscience, 42(6), 1020-1031.

[15]. Yagi, T., et al. (2011). Modeling familial Alzheimer's disease with iPSCs. Neuron, 70(1), 121-134

[16]. Trevisan, K.; Cristina-Pereira, R.; Silva-Amaral, D.; AversiFerreira, T. A. Theories of Aging and the Prevalence of Alzheimer's Disease. BioMed. Research International 2019, 2019, No. e9171424.

[17]. Vogt, A.-C. S.; Jennings, G. T.; Mohsen, M. O.; Vogel, M.; Bachmann, M. F. Alzheimer's Disease: A Brief History ofImmunotherapies Targeting Amyloid β. International Journal of Molecular Sciences 2023, 24 (4), 3895.

[18]. Kidd, M. Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease. Nature 1963, 197, 192−193.

[19]. Beach, T. G. A History of Senile Plaques: From Alzheimer to Amyloid Imaging. Journal of Neuropathology & Experimental Neurology 2022, 81 (6), 387−413.

[20]. Liu, P.-P.; Xie, Y.; Meng, X.-Y.; Kang, J.-S. History and Progress of Hypotheses and Clinical Trials for Alzheimer's Disease. Sig Transduct Target Ther 2019, 4 (1), 1−22.

[21]. Scheltens, P.; De Strooper, B.; Kivipelto, M.; Holstege, H.;Chételat, G.; Teunissen, C. E.; Cummings, J.; van der Flier, W. M. Alzheimer's Disease. Lancet 2021, 397 (10284), 1577−1590.

[22]. Iqbal, K., et al. (2010). Tau pathology in Alzheimer disease and other tauopathies. BiochimicaetBiophysicaActa (BBA) - Molecular Basis of Disease, 1802(5), 1183-1194. https://doi.org/10.1016/j.bbadis.2009.12.001

[23]. Swerdlow, R. H., et al. (2014). Mitochondria and Alzheimer's disease. Molecular Neurobiology, 49(2), 1-19.

[24]. DeKosky, S. T., &Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Annals of Neurology, 27(5), 457-464.

[25]. Jack, C. R., et al. (2010). Tracking pathophysiological processes in Alzheimer's disease: The role of biomarkers. The Lancet Neurology, 9(1), 1-8.

[26]. Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine, 8(6), 595-608.

[27]. Iqbal, K., Liu, F., & Gong, C. X. (2009). Tau and neurodegenerative disease: The story so far. Nature Reviews Neurology, 5(8), 455-466.

[28]. Liddelow, S. A., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541(7638), 481-487.

[29]. Pardo-Moreno, T.; González-Acedo, A.; Rivas-Domínguez, A.;García-Morales, V.; García-Cozar, F. J.; Ramos-Rodríguez, J. J.;Melguizo-Rodríguez, L. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. Pharmaceutics 2022, 14 (6), 1117.

[30]. Atri, A. Current and Future Treatments in Alzheimer's Disease.SeminNeurol 2019, 39 (2), 227−240.

[31]. Grossberg, G. T.; Tong, G.; Burke, A. D.; Tariot, P. N. Present Algorithms and Future Treatments for Alzheimer's Disease. Journal of Alzheimer's Disease 2019, 67 (4), 1157−1171.

[32]. Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects

[33]. Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease

[34]. Reference: Huber, R., et al. (2020). "Blood-based biomarkers for Alzheimer's disease: A critical review." Journal of Alzheimer's Disease, 73(3), 617–634. DOI: 10.3233/JAD-190773

[35]. Reference: Belloy, M. E., et al. (2019). "The APOE ε4 allele and Alzheimer disease: Risk, mechanisms, and therapy." Nature Reviews Neurology, 15(4), 159–171. DOI: 10.1038/s41582-019-0116-9.

[36]. Götz, J., Lim, Y. A., & Eckert, A. (2013). Current concepts and perspectives on Alzheimer's disease. Journal of Alzheimer's Disease, 33(s1), S3-S18. doi:10.3233/JAD-2012-129027.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.67
Volume 5, Issue 1, March 2025

[37]. Reference: Ngandu, T., et al. (2015). "A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent dementia (FINGER): A randomised controlled trial." Lancet, 385(9984), 2255–2263. DOI: 10.1016/S0140-6736(15)60461-5.

[38]. Hampel, H., Prvulovic, D., Teipel, S., Jessen, F., Luckhaus, C., Frölich, L., ...&Pantel, J. (2011). The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology, 95(4), 718-728. doi:10.1016/j.pneurobio.2011.08.014.

[39]. Reference: Cummings, J. L., et al. (2014). "Alzheimer's disease drug development pipeline: 2014." Alzheimer's & Dementia, 10(5), 695–703. DOI: 10.1016/j.jalz.2014.01.014